Research and development of the tumor target anticancer agent using carbohydrate mimic peptide IF7
| Project/Area Number |
15H04982
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
村上 浩雄 浜松医科大学, 医学部附属病院, 助教 (10432212)
柴田 俊章 浜松医科大学, 医学部, 助教 (50529568)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2017: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Keywords | DDS型抗腫瘍薬 / 腫瘍新生血管 / ペプチド / 婦人科腫瘍学 |
|---|
| Outline of Final Research Achievements |
IF7 bound to annexin 1 (Anxa1), which the endothelial surface receptor. Because Anxa1 is a highly specific tumor vasculature surface marker, we confirmed that the IF7 peptide could target anticancer drugs to the tumor vasculature. Then, we synthesized highly-pure new anticancer drug IF7-TXL which conjugate paclitaxel (TXL) with IF7 and investigated the antitumor effect using a cancer bearing mouse. In consideration of a future of IF7, we synthesized D-type IF7 and developed the antineoplastic agent of the hybrid peptide type based on new efficacy. We showed excellent antitumor effect in a highly-detailed pharmacological test.
|
Report
(4 results)
Research Products
(8 results)
-
-
-
-
-
-
-
[Presentation] ペプチド創薬2015
Author(s)
杉原一廣
Organizer
第2回中日本産婦人科セミナー
Place of Presentation
ホテル森の風立山、富山
Year and Date
2015-07-04
Related Report
Invited
-
